We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PrimeCell™ VP of Research and Development Available to Discuss Alternatives to Embryonic Stem Cells
News

PrimeCell™ VP of Research and Development Available to Discuss Alternatives to Embryonic Stem Cells

PrimeCell™ VP of Research and Development Available to Discuss Alternatives to Embryonic Stem Cells
News

PrimeCell™ VP of Research and Development Available to Discuss Alternatives to Embryonic Stem Cells

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "PrimeCell™ VP of Research and Development Available to Discuss Alternatives to Embryonic Stem Cells "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PrimeCell™ Therapeutics has announced that its Vice President of Research and Development, Francisco Silva, will be available to comment on how the company's PrimeCell technology could expedite the movement from stem cell research to therapy.

Derived from adult germ-line stem cells, PrimeCell has been transformed into heart, nerve, bone and cartilage cells.

Countering the conventional wisdom that adult stem cells cannot be successfully reprogrammed to become pluripotent or a greater plasticity, Silva can present data and examples of PrimeCell Therapeutics' discovery.

The PrimeCell technology is relevant as Congress considers legislation authorizing various forms of non-embryonic stem cell research.

WHO: Francisco J. Silva, Executive Vice President of Research & Development for PrimeCell Therapeutics. Silva is a principal contributor to the company's intellectual property portfolio and oversees the development of all therapeutic platforms.

He is responsible for PrimeCell Therapeutics' current scientific progress and designs, and also implements the company's premier research developments.

WHAT: PrimeCell Therapeutics LLC, a newly formed subsidiary of PrimeGen Biotech LLC, is devoted exclusively to adult stem cell reprogramming.

Its next generation stem cell - PrimeCell™ - is the adult, non-embryonic stem cell designed to transforme into any cell type found in the body.

The company has introduced its murine model and initial human results for PrimeCell at several global stem cell conferences.

PrimeCell Therapeutics' research team includes scientists from around the globe, specializing in molecular biology and recombinant DNA technology, biochemistry, cell biology, genetics, neurobiology and more.

EVP Francisco Silva came from the Beckman Research Institute at City of Hope National Medical Center.

Chairman and CEO Thomas C.K. Yuen is renowned for turning technological promise into companies - first as co-founder, co-chairman and COO of AST Research, Inc., then as chairman, CEO and president of SRS Labs.

WHEN: Immediately

HOW: Contact:
         Ken Greenberg
         Edge Communications, Inc.
         818-990-5001
         ken@edgecommunicationsinc.com

Advertisement